Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 9/20 | 0.71 |
| ▸ | LGALS7; LGALS7B | P47929 | 4/20 | 0.69 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.69 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351236 | 1.00 | LGALS3 (0.71) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL5356738 | 0.88 | LGALS3 (0.82) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL5356735 | 0.88 | LGALS3 (0.82) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL5354309 | 0.86 | LGALS3 (0.84) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL5354301 | 0.86 | LGALS3 (0.84) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL17097341 | 0.86 | LGALS3 (0.84) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL19976155 | 0.84 | LGALS3 (0.68) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL19976166 | 0.83 | LGALS3 (1.00) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL17681092 | 0.83 | LGALS3 (1.00) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 | |
| SCHEMBL19976179 | 0.82 | LGALS3 (0.79) | LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150265701-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-09-24 | — | — | US | claimed |
| US-20070207161-A1 | Immunomodulating Compositions and uses Therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2007-09-06 | — | — | US | claimed |
| US-7230096-B2 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2007-06-12 | — | — | US | claimed |
| US-20040147730-A1 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2004-07-29 | — | — | US | claimed |
| US-9770503-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2017-09-26 | — | — | US | disclosed |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150265701-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-09-24 | — | — | US | disclosed |
| US-9050352-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-06-09 | — | — | US | disclosed |
| EP-2591786-A1 | Immunomodulating compositions and uses therefor | Ralph, Stephen John (AU) | 2013-05-15 | — | — | EP | disclosed |
| US-20070207161-A1 | Immunomodulating Compositions and uses Therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2007-09-06 | — | — | US | disclosed |
| US-7230096-B2 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20040147730-A1 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147730-A1 | Inhibitors against galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS7; LGALS7B 8/4885LGALS1 1/4885 |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | LGALS1, LGALS2, LGALS3BP | LGALS3 4/4885LGALS7; LGALS7B 8/4885LGALS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.